Rheumatologists are recommended to have a working knowledge of vaccines for patients with rheumatic disease, and immunization must be individualized based on a shared decision-making process between the healthcare provider and patient.
Symptoms comparison of common upper respiratory disorders including the common cold, influenza, pharyngitis, allergic rhinitis, and the novel COVID-19.
Early initiation of intravenous immunoglobulin and low molecular weight heparin anticoagulant therapy may improve the prognosis of patients with severe COVID-19.
Hospitalized patients withCOVID-19 had higher proportions of nonproductive cough, fatigue, and gastrointestinal symptoms as well as lower severity of illness scores compared with patients with H1N1 influenza.
Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.
Early neuraminidase inhibitor therapy may result in better outcomes in patients hospitalized with influenza B-related pneumonia.
Galactomannan testing for patients with severe influenza in ICU was used always or very often few clinicians.
Results of early research support further development of a synthetic universal influenza vaccine.
Despite the higher effectiveness of the quadrivalent inactivated influenza vaccine against the added B virus lineage, trivalent inactivated influenza vaccine.
Review the results of a recent reader poll on using anti-influenza therapies in patients with community-acquired pneumonia.
